A study based on metastatic melanoma showed that the greater the similarity between PD‐1 and PD‐L1 expression in patients, the better the clinical response to anti‐PD1 therapy and, in turn, the overall survival of metastatic melanoma patients treated with anti‐PD1 was found to be improved, giving justification for the use of biomarkers in helping to guide therapy choices for metastatic melanoma [76]. Here, CD274 is linked to metastatic melanoma.